+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nicotine Addiction - Pipeline Review, H1 2019

  • ID: 4769192
  • Drug Pipelines
  • 65 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Chronos Therapeutics Ltd
  • CV Sciences Inc
  • Indivior Plc
  • Omeros Corp
  • Sosei Heptares
  • MORE
Nicotine Addiction - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction - Pipeline Review, H1 2019, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape.

Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post-traumatic stress disorder and alcoholism. Person experiences withdrawal symptoms at cessation of using, such as shaky hands, sweating, irritability, or rapid heart rate. Treatment includes nicotine replacement therapy (NRT).

Report Highlights

This latest pipeline guide Nicotine Addiction - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Nicotine Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nicotine Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 2 and 18 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Nicotine Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nicotine Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Nicotine Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nicotine Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nicotine Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nicotine Addiction (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nicotine Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nicotine Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Chronos Therapeutics Ltd
  • CV Sciences Inc
  • Indivior Plc
  • Omeros Corp
  • Sosei Heptares
  • MORE
Introduction

Report Coverage

Nicotine Addiction - Overview

Nicotine Addiction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Nicotine Addiction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nicotine Addiction - Companies Involved in Therapeutics Development

Chronos Therapeutics Ltd

CV Sciences Inc

Indivior Plc

Omeros Corp

Sosei Heptares

Nicotine Addiction - Drug Profiles

(cannabidiol + nicotine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

18-MC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-4113 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-6527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-1013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-3009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-4X3256 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EORA-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Noribogaine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

psilocybin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBP-0069330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Mollecules to Antagonize HCRTR1 for Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URB-694 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nicotine Addiction - Dormant Projects

Nicotine Addiction - Discontinued Products

Nicotine Addiction - Product Development Milestones

Featured News & Press Releases

Jul 20, 2017: CV Sciences Cites Recent Clinical Study on Pharmaceutical-Grade CBD Shown to Lower Blood Pressure

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Nicotine Addiction, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Nicotine Addiction - Pipeline by Chronos Therapeutics Ltd, H1 2019

Nicotine Addiction - Pipeline by CV Sciences Inc, H1 2019

Nicotine Addiction - Pipeline by Indivior Plc, H1 2019

Nicotine Addiction - Pipeline by Omeros Corp, H1 2019

Nicotine Addiction - Pipeline by Sosei Heptares, H1 2019

Nicotine Addiction - Dormant Projects, H1 2019

Nicotine Addiction - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Nicotine Addiction, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Chronos Therapeutics Ltd
  • CV Sciences Inc
  • Indivior Plc
  • Omeros Corp
  • Sosei Heptares
Note: Product cover images may vary from those shown
Adroll
adroll